12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prolia denosumab regulatory update

FDA approved an sBLA from Amgen for Prolia denosumab to include treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is already approved in the U.S. and EU to treat osteoporosis in postmenopausal women...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >